뒤로
BioXcel Therapeutics Inc (BTAI) 수입
BTAI 주가 차트
BTAI 수입
BioXcel Therapeutics Inc
$1.43
-2.72%
$-0.04
종가: Mar 24, 16:00:00 GMT-4
$1.45
1.39%
$0.02
프리마켓: Mar 25, 05:52:18 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
BTAI의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
BioXcel Therapeutics Inc BTAI의 지난 분기 매출 실적은 어땠나요?
BioXcel Therapeutics Inc의 매출 추정치는 얼마인가요?
BioXcel Therapeutics Inc의 수익 품질 점수는 얼마인가요?
BioXcel Therapeutics Inc는 언제 수익을 보고하나요?
BioXcel Therapeutics Inc의 예상 수익은 얼마인가요?
BioXcel Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.47
시가
$1.46
일일 범위
$1.4 - $1.47
52주 범위
$1.17 - $8.08
거래량
458.7K
평균 거래량
1.3M
배당수익률
--
EPS(TTM)
-10.41
시가총액
$31.7M
BTAI란 무엇인가요?
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.